NeuroSearch A/S – Status announcement for the period 1

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
NeuroSearch A/S – Status announcement for the period 1 January to 30 September 2015

Announcement 19 November 2015 The NeuroSearch Group (NEUR) posted an operating loss of DKK 5 million (Q3 2014: a loss of DKK 11 million) and a loss after tax of DKK 4 million (Q3: 2014: a loss of DKK 6 million). At 30 September 2015, cash and cash equivalents totalled DKK 80 million (30 September 2014: DKK 83 million).

Update on the company’s activities

  • On 14 October 2015 NeuroSearch was convicted by the Eastern Division of the Danish High Court in an action brought by the Danish State Prosecutor for Serious Economic and International Crime claiming that NeuroSearch was quilty of market manipulation contrary to the rules of the Danish Securities Trading Act. The company was ordered to pay a fine of DKK 5 million.  
  • On 28 October 2015 NeuroSearch filed an application with the Danish Appeals Permission Board seeking permission to appeal the Eastern Division of the Danish High Court’s judgment of 14 October 2015 to the Danish Supreme Court. A permission from Appeals Permission Board to allow the appeals is required because the case has been tried in two instances already.

The board of directors intends, in parallel with the review of the application submitted to the Appeals Permission Board and – assuming that the appeal to the Supreme Court will be permitted – the supreme Court’s review of the case, to seek to expedite a potential disposal or sale of the company or its assets, in order to mitigate as much as possible the consequences of the delay that a review of the case by the Supreme Court will entail. Update on the company's assets The company is seeking a controlled winding up of its remaining assets, while concurrently being open to a possible merger or similar solution. Only two clinical projects are left in the portfolio – NeuroSearch is no longer actively developing the two compounds but is exploring the possibilities of divesting them:

  • Seridopidine for the treatment of CNS disorders (completed Phase I)
  • Ordopidine for the treatment of CNS disorders (completed Phase I) 

Moreover, the company has investments in:

  • NsGene: 26.8%
  • Atonomics: 5.2% 

Licence agreements:

  • Potential milestone payments from Teva Pharmaceuticals of up to DKK 55 million relating to the development of Huntexil®
  • Potential milestone payments and royalties from Saniona 

The value of the assets listed above is subject to substantial uncertainty as no established market exists for such assets. In addition, NeuroSearch calculated the value of its unrecognised tax losses carried forward as of 31 December 2014 to be approximately DKK 2.0 billion, and the company also has deductible timing differences of approximately DKK 0.2 billion, bringing the company's tax assets to a total of DKK 2.2 billion. The tax assets are not recognised, but under certain conditions, a potential buyer of NeuroSearch may be able to utilise all or part of the unrecognised tax assets. Outlook for 2015 In 2015, NeuroSearch expects an operating loss in the range of DKK 7-9 million. The outlook includes neither income from a potential sale of one or more company assets, nor potential income from the company's agreements with Teva, Saniona or others. The provision of DKK 5 million made in 2014 to cover the fine the company was ordered to pay by the Copenhagen City Court and now by Eastern Division of the Danish High Court, is maintained.

Contact Allan Andersen CEO, mobile +45 4016 3864 About NeuroSearch NeuroSearch A/S (NEUR) is listed on NASDAQ OMX Copenhagen A/S.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 407

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 160

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 20

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 292

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 79

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 231

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 308

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 74

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 64

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading

Top 5 Most Recently Viewed Articles

Venezuela's Political Shift and Its Impact on Global Oil Markets

Updated Category News Views 122

Venezuela's Dramatic Political Changes and Market Reactions Recent events in Venezuela have created quite a stir. With the U.S. capturing Nicolás Maduro, the country's president, and extraditing him for trial, one might expect a major upheaval in financial and commodity markets. Surprisingly, the markets seem largely unaffected by this significant geopolitical shift....

Continue Reading
Paradigm Health Pushes Innovative FDA Trial Initiative

Updated Category News Views 27

The FDA's Real-Time Game Changer Just up and submitting their convincing response to the FDA, Paradigm Health's grabbing headlines with a trailblazing initiative right out of Columbus, Ohio. The FDA's Real-Time Clinical Trials (RTCT) proof-of-concept has been a field where Paradigm wields its AI-driven wand, proposing a plan that promises to streamline clinical trial...

Continue Reading
DSV A/S Launches Major Share Buyback Program Announcement

Updated Category News Views 74

DSV A/S Launches Major Share Buyback Program Company Announcement No. 1130 In a strategic effort to boost shareholder value, DSV A/S has launched a share buyback program. This initiative officially began on July 24, 2024, and is expected to wrap up on October 22, 2024. The company plans to repurchase its own shares totaling up to DKK 1,500 million, which corresponds to a...

Continue Reading
Insights into the Growth of the Global Fondant Market Trends

Updated Category News Views 230

Exploring the Global Fondant Market Trends The fondant market is rapidly evolving, driven by a surge in consumer preferences for aesthetically pleasing dessert options. Recent research identifies that the fondant market size, valued at approximately USD 520.45 Million, is anticipated to reach around USD 898.79 Million by 2034, reflecting a robust compound annual growth...

Continue Reading
Innocan Pharma's Strategic Move: Private Placement Details

Updated Category News Views 110

Innocan Pharma's Exciting Private Placement Initiative Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) has announced a significant financial move by planning a non-brokered private placement. This initiative aims to issue up to 3,500,000 units, priced at C$0.20 each, bringing in gross proceeds of up to C$700,000. This offering is designed to expedite the...

Continue Reading